IP Library Granted Patent US 9,132,106
Granted Patent B2
US 9,132,106 · App. 13/826,257 · Granted Sep 15, 2015

Synergistic ophthalmic compositions for disinfecting contact lenses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,106
App. No.
13/826,257
Granted
Sep 15, 2015
Kind
B2
Abstract

Compositions and methods for disinfecting contact lenses using the compositions are disclosed. The compositions include a combination of alexidine and chlorhexidine, which surprisingly causes the composition to exhibit synergistic antimicrobial activity against Candida albicans by reducing a concentration of Candida albicans by at least 1.2 log.

Claims (34)

1. An ophthalmic composition comprising:

from 0.8 ppm to 1.05 ppm alexidine;

from 2 ppm to 5 ppm chlorhexidine; and

from about 0.5 ppm to about 3.3 ppm poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-Ω-[tris(2-hydroxyethyl)ammonio]-dichloride,

wherein the composition exhibits synergistic antimicrobial activity against Candida albicans by reducing a concentration of Candida albicans by at least 2.4 log.

2. The ophthalmic composition of claim 1 , further comprising a chelating agent.

3. The ophthalmic composition of claim 2 , wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA).

4. The ophthalmic composition of claim 1 , wherein EDTA is present at a concentration of from about 0.05% to about 1% by weight per volume.

5. The ophthalmic composition of claim 1 , further comprising a surfactant.

6. The ophthalmic composition of claim 1 , further comprising a buffer agent.

7. The ophthalmic composition of claim 6 , wherein the buffer agent is a boric acid and borate buffering system.

8. The ophthalmic composition of claim 1 , further comprising a tonicity component.

9. The ophthalmic composition of claim 8 , wherein the tonicity component is sodium chloride.

10. The ophthalmic composition of claim 1 , further comprising sodium citrate.

11. The ophthalmic composition of claim 1 , further comprising a viscosity-inducing component.

12. The ophthalmic composition of claim 1 , further comprising from about 0.05% to about 0.25% by weight per volume hydroxypropyl methylcellulose.

13. The ophthalmic composition of claim 1 , further comprising from about 0.039% to about 0.15% by weight per volume hydroxypropyl methylcellulose.

14. An ophthalmic composition comprising:

from 0.8 ppm to 1.05 ppm alexidine;

from 2 ppm to 5 ppm chlorhexidine;

from about 0.5 ppm to about 3.3 ppm poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-Ω-[tris(2-hydroxyethyl)ammonio]-dichloride;

from about 0.04 to about 0.15% by weight per volume of ethylenediaminetetraacetic acid (EDTA);

from about 0.18 to about 0.70% by weight per volume of sodium chloride;

from about 0.50 to about 0.66% by weight per volume of boric acid;

from about 0.15 to about 0.30% by weight per volume of sodium borate;

from about 0.22 to about 0.80% by weight per volume of sodium citrate;

from about 0.03 to about 0.15% by weight per volume of a surfactant; and

from about 0.03 to about 0.25% by weight per volume of a viscosity-inducing component,

wherein alexidine and chlorhexidine together exhibit synergistic antimicrobial activity against Candida albicans by reducing a concentration of Candida albicans by 2.4 to 4.0 log.

15. A method of disinfecting a contact lens comprising: contacting the contact lens with a disinfecting solution, the disinfecting solution including the ophthalmic composition of claim 1 ; and removing the contact lens from the disinfecting solution.

16. The method of claim 15 , wherein the contacting step includes contacting the contact lens with the disinfection solution for at least six hours.

17. The method of claim 15 , wherein the disinfection solution further includes from about 0.05% to about 1% weight per volume ethylenediaminetetraacetic acid (EDTA).

18. The ophthalmic composition of claim 1 , comprising 0.8 ppm alexidine.

19. The ophthalmic composition of claim 1 , comprising 1.05 ppm alexidine.

Assignments (2)
CHANGE OF NAME Recorded Sep 25, 2018
From: ABBOTT MEDICAL OPTICS INC.
To: JOHNSON & JOHNSON SURGICAL VISION, INC.
Reel/Frame 047151/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2013
From: HUTH, STANLEY W.; TRAN, DENISE
To: ABBOTT MEDICAL OPTICS INC.
Reel/Frame 030451/0348 →